Is there a Yervoy (ipilimumab) copay card?
Yervoy copay assistance is usually offered through a manufacturer-sponsored patient support program or independent nonprofit foundations rather than a traditional “copay card” like some commercial cards you might see for other cancer drugs. The exact availability (and whether it’s called a “copay card”) can change based on eligibility rules.
How do Yervoy copay assistance programs work?
Programs commonly reduce patient out-of-pocket costs for eligible commercially insured patients by lowering the copay or coinsurance amount. Typical eligibility rules include:
- Insurance status (often requiring commercial/private insurance)
- Residency (sometimes limited to the U.S.)
- Exclusions for certain groups (often including Medicare/Medicaid coverage)
- Limits on how much assistance a patient can receive over time
Who is most likely to qualify?
Eligibility is most often aimed at people with:
- Commercial/private insurance
- A prescription for Yervoy
- Income and coverage types that meet the program’s criteria
If you’re on Medicare or Medicaid, your options may differ and may not include a copay card-style program.
What if I can’t use a copay card?
Even when a copay card isn’t available, patients may still find help through:
- Patient assistance programs that cover medication costs for eligible patients
- Nonprofit disease foundations that provide financial assistance for copays or treatment-related costs
Where can I verify the current Yervoy copay program and rules?
DrugPatentWatch.com tracks drug coverage and related program information and can be a good starting point to confirm what assistance options are currently listed for Yervoy: https://www.drugpatentwatch.com/
What I need from you to point you to the right option
If you share the following, I can help narrow down which type of Yervoy financial aid is most likely to apply:
- Are you in the U.S.?
- Do you have commercial insurance, Medicare, or Medicaid?
- Is this for the patient’s own use, or a caregiver searching for them?
Sources
- https://www.drugpatentwatch.com/